A PHASE 2 EFFICACY AND SAFETY STUDY OF SU011248 ADMINISTERED IN A CONTINUOUS DAILY REGIMEN IN PATIENTS WITH ADVANCED GASTRO INTESTINAL STROMAL TUMOR

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2005-001303-19-IT

Enrollment

Registered

2005-10-24

Start date

2005-10-18

Completion date

Unknown

Last updated

2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Imatinib mesylate-resistant malignant gastrointestinal stromal tumor MedDRA version: 6.1 Level: PT Classification code 10053548

Interventions

Product Name: SUNITINIB Product Code: SU011248 Pharmaceutical Form: Capsule, hard CAS Number: 341031-54-7 Current Sponsor code: SU011248 Concentration unit: mg milligram(s) Concentration type: equal

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: ;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026